A Phase III Multicenter Randomized, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis
A Phase III Multicenter Randomized, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study.
Inclusion Criteria:
OLE Inclusion Criteria:
Exclusion Criteria:
OLE Exclusion Criteria:
Baltimore, Maryland 21287, United States
Columbus, Ohio 43235, United States
Oklahoma City, Oklahoma 73104, United States
Plano, Texas 75024, United States
Milwaukee, Wisconsin 53215, United States
C. A. B. A., C1055AAF, Argentina
Wuhan, 430030, China
Dresden, 01307, Germany
Shatin, New Territories, Hong Kong
Rome, Lazio 00133, Italy
Bergamo, Lombardy 24127, Italy
Mexico City, Mexico CITY (federal District) 03100, Mexico
Mexico, Tlaxcala 06726, Mexico
Sittard-Geleen, 6162 BG, Netherlands
La Victoria, Lima, Lima 13, Peru
?ory, 44-240, Poland
Plewiska, 62-064, Poland
Santa Maria da Feira, 4520-211, Portugal
Mannouba, 2010, Tunisia
Dnipro, Tavria Okruha, Ukraine
Vinnytsi, 21009, Ukraine